Skip to main content Help with accessibility Skip to main navigation

Adalimumab, etanercept, infliximab and abatacept for moderate rheumatoid arthritis

CCG Approval Status:

Date Added: 29 - Jul - 2021
Body System:

The Pan Mersey Area Prescribing Committee recommends the prescribing of adalimumab, etanercept and infliximab, by specialists only, for the treatment of moderate rheumatoid arthritis after conventional DMARDs have failed and in accordance with NICE TA715.